Related Experiment Video
Updated: Feb 22, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.6K
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
Xavier Mariette1, Connie Chen2, Pinaki Biswas2
1Université Paris-Sud, Assistance publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, INSERM U1184, Le Kremlin Bicêtre, France.
Arthritis Care & Research
|September 24, 2017
Summary
Tofacitinib treatment for rheumatoid arthritis showed stable lymphoma rates over time. Lymphoma characteristics were typical for RA patients, with no significant baseline differences observed.
Area of Science:
- Rheumatology
- Oncology
- Pharmacology
Background:
- Tofacitinib is an oral Janus kinase (JAK) inhibitor used for rheumatoid arthritis (RA).
- Understanding the risk of lymphoma is crucial for patients treated with JAK inhibitors.
Purpose of the Study:
- To characterize lymphoma events within the tofacitinib RA clinical development program.
- To assess lymphoma incidence rates and identify potential risk factors.
Main Methods:
- Analysis of lymphoma events from 19 tofacitinib studies (Phase I-III and long-term extension) up to March 2015.
- Calculation of incidence rates (IR) and standardized incidence ratios (SIR) compared to the SEER database.
- Descriptive case-matched control analysis to identify risk factors.
Main Results:
- 19 lymphomas occurred in 6,194 patients (19,406 patient-years), with an IR of 0.10 per 100 patient-years.
- The age- and sex-adjusted SIR for lymphoma was 2.62 compared to the general population.
- Lymphoma characteristics were typical for RA patients; higher corticosteroid use and certain autoantibodies were noted in cases versus controls.
Conclusions:
- Lymphoma rates remained stable over time during the tofacitinib RA clinical development program.
- Minimal differences in baseline characteristics were observed between patients with and without lymphoma.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:20The JAK-STAT Signaling Pathway
13.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.3K